Subramanian Loganathan

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer

M. Socinski, I. Bondarenko, C. Waller, 2021, Therapeutic advances in medical oncology.

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial

H. Rugo, A. Manikhas, I. Bondarenko, 2017, JAMA.

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19

R. Guleria, S. Joshi, A. Trikha, 2020, medRxiv.

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulin Equivalence‐3) study

O. Klein, S. Athalye, S. Loganathan, 2022, Diabetes, obesity & metabolism.

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE‐2 (Recombinant Human INsulin Equivalence‐2) study

G. Andersen, S. Athalye, S. Loganathan, 2023, Diabetes, obesity & metabolism.